AZN — Recent News Coverage
All news mentioning AZN in ESEN's AI-graded feed
News stories with AZN as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on AZN. See /coverage/AZN for the 30-day aggregate.
MANILATIMES.NET
·
2026-10-26
LOW
BULLISH
CORR0.45
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
$AZN
◈ ESEN AI
HUTCHMED announced positive Phase III data for the SAFFRON trial evaluating ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in a narrow patient population—MET-driven EGFR-mutated non-small cell lung cancer after prio…
INSIDERMONKEY.COM
·
2026-08-13
LOW
NEUTRAL
CORR0.52
Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?
$RPRX
$AZN
◈ ESEN AI
This article presents a comparative analysis of two distinct biopharma business models: Royalty Pharma (RPRX), which acquires royalty streams from approved drugs, versus AstraZeneca (AZN), which pursues integrated drug …
INSIDERMONKEY.COM
·
2026-08-11
NEUTRAL
BEARISH
CORR0.42
AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk
$AZN
$BMY
◈ ESEN AI
AstraZeneca (AZN) experienced a significant 9% single-day decline on merger speculation involving Bristol-Myers Squibb (BMY), marking the largest drop since 2020. Market skepticism around the potential combination signa…
SEEKINGALPHA
·
2026-08-11
HIGH
BULLISH
CORR0.72
AstraZeneca held talks with Bristol-Myers through spring, summer - FT
$AZN
$BMY
◈ ESEN AI
AstraZeneca and Bristol-Myers Squibb conducted sustained merger discussions over multiple quarters, signaling serious strategic intent to consolidate two major pharmaceutical players. The protracted negotiation timeline…
FINANCE.YAHOO.COM
·
2026-08-11
NEUTRAL
NEUTRAL
CORR0.52
Hedge Funds are Bullish on AstraZeneca PLC (AZN)
$AZN
◈ ESEN AI
AstraZeneca delivered a mixed earnings narrative: the pharmaceutical firm beat consensus earnings expectations with core EPS of $2.63 versus $2.48 forecast, demonstrating operational execution and profitability resilien…
FINANCE.YAHOO.COM
·
2026-08-11
NEUTRAL
BULLISH
CORR0.58
A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?
$BCRX
$AZN
$AMGN
$SNY
$NVS
◈ ESEN AI
BioCryst has achieved profitability while its rare-disease therapeutic Orladeyo generates material cash flows, creating a compelling acquisition target in the specialty pharma space. The achievement represents meaningfu…
SEEKINGALPHA.COM
·
2026-08-05
NEUTRAL
BULLISH
CORR0.58
Wall Street Lunch: Parks, Pixar Power Disney
$DIS
$UBER
$AZN
$BMY
◈ ESEN AI
Disney is displaying meaningful operational momentum across multiple revenue streams, with theatrical blockbuster performance and theme park strength providing dual tailwinds to earnings capacity. The asset mix suggests…
SEEKINGALPHA
·
2026-08-05
NEUTRAL
BEARISH
CORR0.15
Bristol-Myers falls on report there are no talks going on with AstraZeneca
$BMY
$AZN
◈ ESEN AI
Bristol-Myers Squibb (BMY) faced downward pressure following reports that no active merger or acquisition discussions are underway with AstraZeneca (AZN). The denial of ongoing talks suggests market speculation about a …
SEEKINGALPHA
·
2026-08-04
HIGH
BULLISH
CORR0.72
Bristol-Myers Squibb, AstraZeneca deal talks remain active - report
$BMY
$AZN
◈ ESEN AI
Bristol-Myers Squibb (BMY) and AstraZeneca (AZN) remain engaged in active merger discussions, according to reporting. M&A negotiations of this scale represent a potential industry-consolidating transaction that could re…
SEEKINGALPHA
·
2026-08-03
NEUTRAL
NEUTRAL
CORR0.15
Potential AstraZeneca purchase of Bristol-Myers unlikely for now - analyst
$AZN
$BMY
◈ ESEN AI
Analyst commentary on a potential acquisition of Bristol-Myers Squibb (BMY) by AstraZeneca (AZN) suggests such a transaction remains unlikely in the near term. This represents a reassessment of earlier market speculatio…
FINANCE.YAHOO.COM
·
2026-08-03
HIGH
BEARISH
CORR0.72
AstraZeneca shares slump after $400bn BMS merger rumours
$AZN
$BMY
◈ ESEN AI
AstraZeneca shares declined on merger speculation involving Bristol Myers Squibb, with reports suggesting a potential $400 billion combination. The immediate market reaction penalized AZN, indicating investor concern ab…
SEEKINGALPHA
·
2026-08-03
NEUTRAL
NEUTRAL
CORR0.35
AstraZeneca tops pharma growth rankings while Bristol Myers trails amid merger talks
$AZN
$BMY
◈ ESEN AI
AstraZeneca has outperformed peer benchmarks in pharma growth metrics, signaling stronger pipeline execution and commercial momentum relative to competitors. This reflects operational discipline and successful market po…
FINANCE.YAHOO.COM
·
2026-08-03
NEUTRAL
BULLISH
CORR0.72
Wall St futures edge up on Mideast deal hopes; healthcare in focus
$AMD
$AZN
$WDC
◈ ESEN AI
U.S. equity futures opened the week with modest upside momentum driven primarily by geopolitical de-escalation signals in the Middle East. The reported tensions easing represent a tail-risk reduction for markets, partic…
SEEKINGALPHA.COM
·
2026-08-03
NEUTRAL
NEUTRAL
CORR0.42
Wall Street Breakfast Podcast: Say Hello To Qwen3.8-Max (undefined:BABA)
$BABA
$AZN
$BMY
◈ ESEN AI
Alibaba announced Qwen3.8-Max, advancing its competitive position in the large language model race. This launch represents continued investment in generative AI infrastructure and signals intensifying competition agains…
FORTUNE.COM
·
2026-08-02
HIGH
BULLISH
CORR0.72
AstraZeneca said to have explored Bristol Myers merger
$AZN
$BMY
◈ ESEN AI
AstraZeneca has explored a potential merger with Bristol Myers Squibb, a $133 billion pharmaceutical player, signaling strategic intent to consolidate market position. Pharma M&A activity of this magnitude typically com…
SEEKINGALPHA
·
2026-08-02
HIGH
BULLISH
CORR0.72
AstraZeneca, Bristol Myers held merger talks, Financial Times reports
$AZN
$BMY
◈ ESEN AI
AstraZeneca and Bristol Myers Squibb engagement in merger discussions represents a potentially transformational consolidation event in the pharmaceutical sector. Large-cap M&A activity of this magnitude typically comman…
MANILATIMES.NET
·
2026-07-30
NEUTRAL
BULLISH
CORR0.55
HUTCHMED Reports 2026 Interim Results
$AZN
◈ ESEN AI
HUTCHMED's interim 2026 results demonstrate sustained momentum in China's pharmaceutical market, with flagship products ELUNATE® and SULANDA® both posting over 40% growth. This recovery trajectory reflects strengthening…
SEEKINGALPHA.COM
·
2026-07-27
NEUTRAL
NEUTRAL
CORR0.42
AstraZeneca PLC (AZN) Q2 2026 Earnings Call Transcript
$AZN
◈ ESEN AI
AstraZeneca released its Q2 2026 earnings transcript, providing management commentary on operational and financial performance during the period. The earnings call transcript itself represents a standard disclosure even…
RTTNEWS.COM
·
2026-07-27
NEUTRAL
BULLISH
CORR0.72
Easing Middle East Tensions May Lead To Initial Strength On Wall Street
$NVDA
$AZN
◈ ESEN AI
Market positioning ahead of Monday's open reflects geopolitical risk-off sentiment as Middle East tensions ease, creating a tactical relief rally backdrop. Index futures signaling higher opens suggest investor appetite …
SEEKINGALPHA.COM
·
2026-07-27
NEUTRAL
NEUTRAL
CORR0.45
AstraZeneca PLC 2026 Q2 - Results - Earnings Call Presentation (NYSE:AZN) 2026-07-27
$AZN
◈ ESEN AI
AstraZeneca released its Q2 2026 earnings presentation, a routine disclosure of financial and operational results via investor call. This represents standard quarterly reporting by a major pharmaceutical company and doe…
RTTNEWS.COM
·
2026-07-27
NEUTRAL
NEUTRAL
CORR0.32
AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View
$AZN
◈ ESEN AI
AstraZeneca delivered a mixed earnings narrative in Q2, with pre-tax profit declining but EPS growth offsetting underlying weakness. The earnings beat on a per-share basis reflects lower tax expenses rather than operati…
FINANCE.YAHOO.COM
·
2026-07-27
HIGH
BULLISH
CORR0.72
Stock market today: Dow, S&P 500, Nasdaq futures rise as oil tumbles, investors brace for busy week
$AAPL
$MSFT
$AZN
$SBUX
◈ ESEN AI
Equity futures are advancing as crude oil prices retreat, signaling a potential relief rally ahead of what market participants are branding as the quarter's most event-dense trading week. The combination of falling ener…
SEEKINGALPHA.COM
·
2026-07-27
NEUTRAL
BULLISH
CORR0.35
AstraZeneca PLC declares $1.06 interim dividend
$AZN
◈ ESEN AI
AstraZeneca announced an interim dividend of $1.06 per share, payable September 8 to shareholders of record as of August 7. The ex-dividend date is also August 7, establishing the standard dividend mechanics timeline. T…
SEEKINGALPHA.COM
·
2026-07-24
NEUTRAL
NEUTRAL
CORR0.35
AstraZeneca PLC Q2 2026 Earnings Preview
$AZN
◈ ESEN AI
AstraZeneca (AZN) will report Q2 2026 results on July 27th with consensus EPS guidance at $1.27, a routine earnings announcement that will serve as a catalyst for near-term stock direction pending actual results versus …
FINANCE.YAHOO.COM
·
2026-07-13
NEUTRAL
BULLISH
CORR0.42
UBS stays positive on AstraZeneca ahead of second-quarter results
$AZN
◈ ESEN AI
UBS has reiterated a positive stance on AstraZeneca (AZN) ahead of its second-quarter earnings release, maintaining a 'buy' rating on the British pharmaceutical giant. This analyst validation reflects confidence in the …
SEEKINGALPHA.COM
·
2026-07-09
HIGH
BEARISH
CORR0.42
AstraZeneca And Ionis Pharma Rocked By Heart Disease Fail - Why You Shouldn't Panic (AZN)
$AZN
$IONS
◈ ESEN AI
AstraZeneca (AZN) and Ionis Pharma (IONS) face significant near-term headwinds following the Wainua Phase 3 trial failure in heart disease treatment. This late-stage clinical setback eliminates a previously anticipated …
ETFTRENDS.COM
·
2026-07-07
NEUTRAL
BULLISH
CORR0.72
Inside THNR: A Leaner Approach to Weight Loss Investing
$LLY
$AZN
$NVO
$REGN
$ABBV
◈ ESEN AI
The THNR ETF represents a thematic investment vehicle focused on the accelerating GLP-1 drug category and weight loss therapeutics market. This specialized fund provides concentrated exposure to LLY, AZN, and NVO, which…
SEEKINGALPHA.COM
·
2026-07-07
LOW
NEUTRAL
CORR0.15
AstraZeneca PLC (AZN) Discusses Progress in Sustainability Strategy and the Role of AI in Healthcare Innovation - Slideshow (NYSE:AZN) 2026-07-06
$AZN
◈ ESEN AI
AstraZeneca has released a slide deck detailing progress on its sustainability strategy and the integration of artificial intelligence within healthcare innovation frameworks. This represents a non-event disclosure of c…
SEEKINGALPHA.COM
·
2026-07-06
NEUTRAL
BULLISH
CORR0.42
AstraZeneca PLC (AZN) Discusses Progress in Sustainability Strategy and the Role of AI in Healthcare Innovation Transcript
$AZN
◈ ESEN AI
AstraZeneca (AZN) has outlined progress on its sustainability initiatives while emphasizing AI integration as a cornerstone of future healthcare innovation. This dual-track messaging suggests management confidence in lo…
FINANCE.YAHOO.COM
·
2026-07-05
NEUTRAL
BULLISH
CORR0.42
Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance
$AZN
◈ ESEN AI
AstraZeneca has entered a strategic collaboration with Abbisko Therapeutics to develop a combination immunotherapy targeting EGFR-mutated and PD-L1 positive NSCLC, following China regulatory clearance. This partnership …
GREATERFOOL.CA
·
2026-07-04
LOW
BEARISH
CORR0.15
Bollixed — Greater Fool – Authored by Garth Turner – The Troubled Future of Real Estate
$HSBC
$AZN
◈ ESEN AI
This article addresses UK political instability stemming from Prime Minister Keir Starmer's resignation, marking the fifth leadership change in as many years. The rapid turnover signals deepening institutional weakness …
SEEKINGALPHA.COM
·
2026-07-02
NEUTRAL
BULLISH
CORR0.45
AstraZeneca inks kidney therapy deal with CSPC (AZN:NYSE)
$AZN
$CSPCY
◈ ESEN AI
AstraZeneca has announced a strategic partnership with CSPC Pharmaceutical Group valued at up to $1.77 billion for the joint development of kidney disease therapeutics. This represents a modest but meaningful expansion …
SEEKINGALPHA.COM
·
2026-06-11
NEUTRAL
NEUTRAL
CORR0.15
AstraZeneca PLC (AZN) Presents at American Diabetes Association (ADA) 86th Scientific Sessions - Slideshow (NYSE:AZN) 2026-06-11
$AZN
◈ ESEN AI
AstraZeneca (AZN) presented clinical data and insights at the American Diabetes Association's 86th Scientific Sessions, a routine industry participation event. Such conference presentations typically showcase existing o…
EXPLORE OTHER FILTERS